These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32075013)

  • 1. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
    De La Franier B; Thompson M
    Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid.
    Davoudian K; Spagnolo S; Lotay N; Satkauskas M; Mészáros G; Hianik T; Keresztes Z; Walker G; Thompson M
    Biosensors (Basel); 2024 Jun; 14(6):. PubMed ID: 38920591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
    Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupled Electrostatic and Hydrophobic Destabilisation of the Gelsolin-Actin Complex Enables Facile Detection of Ovarian Cancer Biomarker Lysophosphatidic Acid.
    Davoudian K; Bhattacharya S; Thompson D; Thompson M
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology.
    Franier B; Thompson M
    Biosens Bioelectron; 2019 Jun; 135():71-81. PubMed ID: 31003031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
    Sedláková I; Vávrová J; Tošner J; Hanousek L
    Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
    Lu Z; Chen Y; Hu Z; Hu C
    Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
    Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
    Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
    Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
    Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
    Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
    Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity-based electrochemical biosensor with antifouling properties for detection of lysophosphatidic acid, a promising early-stage ovarian cancer biomarker.
    Ahmadi S; Lotay N; Thompson M
    Bioelectrochemistry; 2023 Oct; 153():108466. PubMed ID: 37244204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for quantifying lysophosphatidic acid in body fluids: a review.
    Jesionowska A; Cecerska E; Dolegowska B
    Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
    Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
    Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of lysophosphatidic acids by capillary electrophoresis with indirect ultraviolet detection.
    Chen YL; Xu Y
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):355-63. PubMed ID: 11334351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Tailoring of Electrostatic and Hydrophobic Interactions for Rapid and Specific Recognition of Lysophosphatidic Acid, an Early-Stage Ovarian Cancer Biomarker.
    Wang Y; Pei H; Jia Y; Liu J; Li Z; Ai K; Lu Z; Lu L
    J Am Chem Soc; 2017 Aug; 139(33):11616-11621. PubMed ID: 28782946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophospholipids are potential biomarkers of ovarian cancer.
    Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.